

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
June 29, 2011

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of incorporation)

0-21116  
(Commission File No.)

87-0500306  
(IRS Employer Identification  
Number)

3838 West Parkway Boulevard  
Salt Lake City, Utah 84120  
(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure**

On June 29, 2011, USANA Health Sciences, Inc. issued a press release disclosing material nonpublic information regarding its preliminary financial results for its second quarter ending July 2, 2011. A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference. The company will also post this document on its corporate website, [www.usanahealthsciences.com](http://www.usanahealthsciences.com).

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Exhibit 99 Press release issued by USANA Health Sciences, Inc. dated June 29, 2011 (furnished herewith).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**USANA HEALTH SCIENCES, INC.**

**By:** /s/ G. Douglas Hekking

G. Douglas Hekking, Chief Financial Officer

Date: June 29, 2011

## USANA Provides Preliminary Second Quarter Results

- *Net Sales Expected to Exceed \$147.0 Million; EPS at or above \$0.85*
- *Leadership Team Transition Smoothly Implemented*
- *New Leadership Team Revises China Strategy*

SALT LAKE CITY--(BUSINESS WIRE)--June 29, 2011--USANA Health Sciences, Inc. (NYSE: USNA) today reported that preliminary net sales for its fiscal second quarter ending July 2, 2011 are expected to exceed \$147.0 million and earnings per share for the quarter are expected to be at or above \$0.85. Earnings per share for the period will benefit by approximately \$0.06 due to the recapture of unvested equity compensation expense related to the departure of certain executives from the Company. The Company plans to release final results for the second quarter, as well as update its annual financial guidance, after market close on July 26<sup>th</sup>. The Company will host a conference call to discuss its progress on Wednesday morning, July 27<sup>th</sup>.

Chief Executive Officer Dave Wentz said, "Our senior management transition announced on May 10, 2011 was smoothly and successfully implemented during the quarter, reflecting the strong leadership qualities and dedication of our management team, as well as the depth of our organization. We are grateful for the significant amount of time and input our Associate leaders provided our management team during this transition. After considering input from our Associate leaders, Deborah Woo, our new President of Asia Pacific, recommended a revised approach to our integration strategy for BabyCare in China. We implemented our new strategy mid-quarter and believe this revised approach contributed to our results for the quarter."

---

Mr. Wentz continued, “The revised strategy entails a more gradual and natural transition of sales and Associate organizations between our Hong Kong market and BabyCare’s market in mainland China. While this revised approach helped drive our second quarter performance, the intended objective of this change is to drive long-term sales and customer growth in this region.”

**About USANA**

USANA develops and manufactures high-quality nutritional, personal care, and weight-management products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, and the United Kingdom. Additionally, USANA’s wholly-owned subsidiary, BabyCare, Ltd., operates a direct selling business in China. More information on USANA can be found at <http://www.usanahealthsciences.com>.

**Safe Harbor**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

**CONTACT:**

USANA Health Sciences, Inc.

Investors contact:

Patrique Richards, 801-954-7961

Investor Relations

[investor.relations@us.usana.com](mailto:investor.relations@us.usana.com)

or

Media contact:

Dan Macuga, 801-954-7280

Public Relations